Ribomic

Ribomic EPS

The Earnings per Share (EPS) of Ribomic (4591.T) as of Oct 30, 2026 is -20.60 JPY. In the previous year, Earnings per Share (EPS) was -19.12 JPY — a change of 7.75% (lower).

EPS

-20.60JPY

YoY

7.75%

Last updated:

Earnings per Share (EPS) of Ribomic is 2026 -20.60 JPY. Earnings per Share (EPS) of Ribomic was 2025 -19.12 JPY. It decreases by 7.75% lower compared to the previous year.

The Ribomic EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2019
-51.97 JPY
Jan 1, 2020
-30.64 JPY
Jan 1, 2021
-42.13 JPY
Jan 1, 2022
-53.16 JPY
Jan 1, 2023
-46.33 JPY
Jan 1, 2024
-24.56 JPY
Jan 1, 2025
-19.12 JPY
Jan 1, 2026
-20.60 JPY
The Ribomic EPS history
YEAREPSYoY
-20.60JPY+7.75%
-19.12JPY-22.14%
-24.56JPY-47.00%
-46.33JPY-12.84%
-53.16JPY+26.19%
-42.13JPY+37.50%
-30.64JPY-41.05%
-51.97JPY-0.69%
-52.33JPY+8.88%
-48.07JPY+97.12%
-24.38JPY-13,262.99%
0.19JPY-104.86%
-3.81JPY-23.32%
-4.97JPY-11.86%
-5.64JPY-86.00%
-40.27JPY+247.63%
-11.59JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Earnings per Share (EPS) of Ribomic is -20.60 JPY in 2026.

Earnings per Share (EPS) of Ribomic changed from -19.12 JPY to -20.60 JPY, representing a 7.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Ribomic since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Ribomic

All Key Metrics — Ribomic